The path to understanding and overcoming advanced cancer begins with Intermountain Precision Genomics' TheraMap test, a personalized approach to cancer care.

By customizing care to patients’ DNA and matching them with targeted treatments, TheraMap can help improve results and reduce costs. This way, patients can spend less time worrying about treatment and enjoy an improved quality of life.

Why TheraMap

By streamlining the process of genomics sequencing, implementing clinical guidance, and shifting focus to targeted therapies, our advanced-stage cancer patients enjoy a better quality of life.

TheraMap simplifies patient care for oncologists by providing straightforward interpretations, prioritization of therapies, and the next steps specific to each patient’s genomic results.

TheraMap Testing Options

  • TheraMap: Solid Tumor
    TheraMap: Solid Tumor is a hybrid capture DNA- and RNA-based test that detects SNV, INDELs, Copy Number Variants (CNV), and fusions in solid tumors. TheraMap is validated for all solid tumor types and includes sequencing over 500 genes identified as relevant to cancer treatment, relevant gene fusion events, including NTRK fusions, as well as the important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers.
  • In cases where the specimen is scant, Intermountain Precision Genomics can reflex to a smaller version of the solid tumor panel that tests fewer genes (58 total), but still detects all the NCCN-specified genes, including NTRK fusions. Providers with concerns that a specimen may be insufficient are encouraged to select TheraMap: Solid Tumor with Reflex when ordering

Gene List

TheraMap analyzes both DNA and RNA, detecting SNVs, INDELS, Copy Number Variants (CNV), gene fusions, and breakpoints in solid tumors. In contrast to amplicon or other targeted methods, TheraMap has a hybrid capture technology that is one of the most sensitive methodologies for detecting gene fusion events from known and novel partners. TheraMap is one of the first available clinical tests that can detect any oncogenic fusions event in NTRK1, NTRK2, and NTRK3, a critical biomarker with the recent approval of Vitrakvi (larotrectinib).

View the gene lists here:

Our Process

  1. The ordering oncologist first completes the test requisition, which alerts Intermountain Precision Genomics to begin the sample acquisition process.
  2. Once the specimen is received, the Intermountain Precision Genomics CAP and CLIA certified laboratory utilizes state-of-the-art next-generation sequencing, additional molecular methods, and proprietary data analytics, to identify all clinically relevant cancer mutations.
  3. The Molecular Tumor Board, a group of clinical experts and precision medicine key opinion leaders then reviews TheraMap Solid Tumor results and provides recommendations for specific therapies and treatments.
  4. A report is sent to the ordering provider with treatment information on variants that are clinically actionable and a list of available clinical trials.

Order TheraMap

Three ways to order:

Specimen Requirements

Please reference this document for specimen and shipping requirements. 

Sample Report

Your TheraMap test results will come as formatted in this sample report.

Billing/Insurance Information

TheraMap: Solid Tumor* has Medicare coverage in medically relevant cases and additionally, many private payers cover this type of testing for late-stage cancer patients. Please work with the patient’s insurance company for any pre-authorization requirements prior to ordering. If you have any questions, or would like assistance, please call our customer service representatives at (435) 251-5780. *Please note that a decision on Medicare coverage is pending for the reflex version of the panel.


Dr. Derrick Haslem, MD, Associate Medical Director of Oncology, et al, composed a study on precision cancer medicine in patients with advanced-stage cancer, finding those who received precision medicine treatment had improved clinical outcomes without increasing healthcare costs. Download and read the publication: Haslem et al | Journal of Oncology Practice.